Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)
ClinicalTrials.gov ID
NCT00533481
Lead Sponsor
Merck Sharp & Dohme LLCINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
497Actual
Last Update Posted
Sep 16, 2016Estimated
Start Date
Feb 2004
Primary Completion Date
Dec 2004Actual
Completion Date
Dec 2004Actual
Brief Summary
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.
Obesity
MK0557
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)
Exclusion Criteria:
Subject has high blood pressure or is taking any high blood pressure medicine
History of psychiatric disorder, stroke, or heart disease